- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
- 个人中心
- 退出登录
浏览全部资源
扫码关注微信
- Journal Information
- Journal Introduction
- Editorial Board
- Youth Editorial Board
- Editorial Board Charter
- Subscriptions
- Archive
- Current Issue
- Past Issues
- Priority Publication
- Virtual Collection
- Recommended Articles
- Submission
- Submission Process
- Submission Guidelines
- Download
- Contact us
- For Reviewers
- Guidelines for Reviewers
- Peer Reviewed Policies
- Statement and Policies
- Ethics and Malpractice
- Research Ethics Policies
- Repetition Detection
- Corrections and Retractions
- Editorial Policies
- Open Access Statement
- Website Responsibility
Monte Carlo simulation-based optimization of the rivaroxaban regimen for anticoagulation in patients with different classes of renal function
- ZHONGGUO YAOFANG Vol. 35, Issue 24, Pages: 3016-3022(2024)
- 作者机构：
1.河北医科大学研究生学院，石家庄 050017
2.河北省人民医院药学部，石家庄 050051
3.河北省临床药学重点实验室，石家庄 050051
- 作者简介：
- 基金信息：
DOI：10.6039/j.issn.1001-0408.2024.24.09
CLC： R969.3;R973+2Received：31 March 2024，
Revised：2024-12-04，
Accepted：05 December 2024，
Published：30 December 2024
- 稿件说明：
移动端阅览
余巧玲,翟葳葳,李宇蒙,等.基于蒙特卡罗模拟优化不同肾功能分级患者的利伐沙班抗凝方案[J].中国药房,2024,35(24):3016-3022.
YU Qiaoling,ZHAI Weiwei,LI Yumeng,et al.Monte Carlo simulation-based optimization of the rivaroxaban regimen for anticoagulation in patients with different classes of renal function[J].ZHONGGUO YAOFANG,2024,35(24):3016-3022.
余巧玲,翟葳葳,李宇蒙,等.基于蒙特卡罗模拟优化不同肾功能分级患者的利伐沙班抗凝方案[J].中国药房,2024,35(24):3016-3022. DOI： 10.6039/j.issn.1001-0408.2024.24.09.
YU Qiaoling,ZHAI Weiwei,LI Yumeng,et al.Monte Carlo simulation-based optimization of the rivaroxaban regimen for anticoagulation in patients with different classes of renal function[J].ZHONGGUO YAOFANG,2024,35(24):3016-3022. DOI： 10.6039/j.issn.1001-0408.2024.24.09.
摘要
目的
2
优化不同肾功能分级患者的利伐沙班抗凝给药方案。
方法
2
根据利伐沙班药品说明书及患者实际服药情况设定给药方案，根据河北省人民医院患者利伐沙班谷浓度参考范围及国际血液学标准化委员会推荐的利伐沙班实验室监测浓度参考范围，设置目标浓度范围区间及分段区间，采用Oracle Crystal Ball软件（V11.1.2.4），通过蒙特卡罗模拟考察不同给药方案的利伐沙班稳态谷浓度落在各目标浓度范围区间的中靶概率。
结果
2
共纳入非瓣膜性房颤患者97例，其检测利伐沙班稳态谷浓度125次、中位稳态谷浓度为32.2 ng/mL；共纳入静脉血栓患者121例，其检测利伐沙班稳态谷浓度159次、中位稳态谷浓度为31.0 ng/mL。非瓣膜性房颤患者的稳态谷浓度参考范围为12～137、3～153 ng/mL，静脉血栓患者的稳态谷浓度参考范围为6～239、3～224 ng/mL。蒙特卡罗模拟结果显示，对于非瓣膜性房颤患者，当肾小球滤过率（eGFR）为0～30 mL/min时，其利伐沙班最佳给药方案为每次5 mg，每天1次；当eGFR为＞30～60 mL/min时，其利伐沙班最佳给药方案为每次10～20 mg，每天1次或每次5 mg，每天2次；当eGFR为＞60～90 mL/min时，其利伐沙班最佳给药方案为每次15～30 mg，每天1次或每次5～10 mg，每天2次；当eGFR为＞90～120 mL/min时，其利伐沙班最佳给药方案为每次25～30 mg，每天1次或每次5～15 mg，每天2次。对于静脉血栓患者，当eGFR为0～30 mL/min时，不推荐每天使用利伐沙班超过5 mg；当eGFR为＞30～60 mL/min时，其利伐沙班最佳给药方案为每次5 mg，每天1次；当eGFR为＞60～90 mL/min时，其利伐沙班最佳给药方案为每次25～30 mg，每天1次或每次5～15 mg，每天2次；当eGFR为＞90～120 mL/min时，其利伐沙班最佳给药方案为每次10～15 mg，每天2次。
结论
2
临床对肾功能严重损伤的患者应谨慎选择利伐沙班抗凝。利伐沙班谷浓度参考范围宽泛、个体差异性大，可通过蒙特卡罗模拟方法，结合患者肾功能，个体化选择利伐沙班服药剂量和频次。
Abstract
OBJECTIVE
2
To optimize the rivaroxaban dosing regimen for anticoagulation in patients with different renal function levels.
METHODS
2
The administration regimen was determined based on the drug instructions for rivaroxaban and the actual medication situation of the patient. The target concentration range and the subsection interval were established using rivaroxaban blood minimum concentration for patients from Hebei General Hospital and reference range of rivaroxaban laboratory monitoring concentration recommended by International Council for Standardization in Hematology. The probability of different dosing regimens in each target concentration range was investigated with Monte Carlo simulation using Oracle Crystal Ball software （V11.1.2.4）.
RESULTS
2
A total of 97 patients with non-valvular atrial fibrillation were enrolled and the minimum concentration of rivaroxaban was tested 125 times with a median trough concentration of 32.2 ng/mL； a total of 121 patients with venous thrombosis were enrolled and the minimum concentration was tested 159 times with a median minimum concentration of 31.0 ng/mL. The reference range for steady-state minimum concentration in patients with non-valvular atrial fibrillation was 12-137 and 3-153 ng/mL， while the reference range for steady-state minimum concentration in patients with venous thrombosis was 6-239 and 3-224 ng/mL. Monte Carlo simulation results showed that in patients with non-valvular atrial fibrillation， the optimal rivaroxaban dosing regimen for patients with glomerular filtration rate （eGFR） 0-30 mL/min was 5 mg once daily； for patients with eGFR＞30-60 mL/min， the optimal dosing regimen was 10-20 mg once daily or 5 mg twice daily； for patients with eGFR＞60-90 mL/min， the optimal dosing regimen was 15-30 mg once daily or 5-10 mg twice daily； for patients with eGFR＞90-120 mL/min， the optimal dosing regimen was 25-30 mg once daily or 5-15 mg twice daily. For patients with venous thrombosis， it is not recommended to use rivaroxaban more than 5 mg once daily for patients with eGFR 0-30 mL/min； the optimal dosing regimens of rivaroxaban were 5 mg once daily for patients with eGFR＞30-60 mL/min， 25-30 mg once daily or 5-15 mg twice daily for patients with eGFR＞60-90 mL/min， 10-15 mg twice daily for patients with eGFR＞90-120 mL/min.
CONCLUSIONS
2
Rivaroxaban should be selected carefully as the anticoagulants for patients with severe renal function impairment. Rivaroxaban possesses a wide reference range in the minimum concentration and considerable individual variability. The dosage and frequency of rivaroxaban can be personalized through the Monte Carlo simulation method， taking into account patients’ renal function.
关键词
Keywords
references
VAN DER LINDEN L ， HIAS J ， VANASSCHE T . The value and limitations of new oral anticoagulant plasma level assessments [J ] . Eur Heart J Suppl，2022 ， 24 （Suppl. A）： A32 - A41 .
TOOROP M M A ， LIJFERING W M ， SCHERES L J J . The relationship between DOAC levels and clinical outcomes：the measures tell the tale [J ] . J Thromb Haemost ， 2020 ， 18 （ 12 ）： 3163 - 3168 .
ZHANG F L ， CHEN X H ， WU T T ， et al . Population pharmacokinetics of rivaroxaban in Chinese patients with non-valvular atrial fibrillation：a prospective multicenter study [J ] . Clin Pharmacokinet ， 2022 ， 61 （ 6 ）： 881 - 893 .
TOOROP M M A ， VAN REIN N ， NIERMAN M C ， et al . Inter- and intra-individual concentrations of direct oral anticoagulants：the KIDOAC study [J ] . J Thromb Haemost ， 2022 ， 20 （ 1 ）： 92 - 103 .
DUNOIS C . Laboratory monitoring of direct oral anti-coagulants（DOACs） [J ] . Biomedicines ， 2021 ， 9 （ 5 ）： 445 .
DOUXFILS J ， ADCOCK D M ， BATES S M ， et al . 2021 update of the International Council for Standardization in haematology recommendations for laboratory measurement of direct oral anticoagulants [J ] . Thromb Haemost ， 2021 ， 121 （ 8 ）： 1008 - 1020 .
DOUXFILS J ， AGENO W ， SAMAMA C M ， et al . Laboratory testing in patients treated with direct oral anticoagulants：a practical guide for clinicians [J ] . J Thromb Haemost ， 2018 ， 16 （ 2 ）： 209 - 219 .
BANACK H R ， HAYES-LARSON E ， MAYEDA E R . Monte Carlo simulation approaches for quantitative bias analysis：a tutorial [J ] . Epidemiol Rev ， 2022 ， 43 （ 1 ）： 106 - 117 .
张继稳 ， 钟大放 ， 毕殿洲 . 单室模型药物血管外给药零级、一级释放药物动力学 [J ] . 中国药理学通报 ， 2005 ， 21 （ 2 ）： 245 - 248 .
ZHANG J W ， ZHONG D F ， BI D Z . Pharmacokinetics of zero-order release and first-order release of mono-compartment drugs administered by non-parenteral route [J ] . Chin Pharmacol Bull ， 2005 ， 21 （ 2 ）： 245 - 248 .
ESMAEILI T ， REZAEE M ， ABDAR ESFAHANI M ， et al . Rivaroxaban population pharmacokinetic and pharmacodynamic modeling in Iranian patients [J ] . J Clin Pharm Ther ， 2022 ， 47 （ 8 ）： 1284 - 1292 .
LIU X Q ， ZHANG Y F ， DING H Y ， et al . Population pharmacokinetic and pharmacodynamic analysis of rivaroxaban in Chinese patients with non-valvular atrial fibrillation [J ] . Acta Pharmacol Sin ， 2022 ， 43 （ 10 ）： 2723 - 2734 .
XU X S ， MOORE K ， BURTON P ， et al . Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes [J ] . Br J Clin Pharmacol ， 2012 ， 74 （ 1 ）： 86 - 97 .
LI Z ， YANG S Y ， HUA Z X ， et al . Population pharmacokinetics of rivaroxaban in Chinese deep vein thrombosis patients and the exposure simulation for dosing recommendation [J ] . Naunyn Schmiedebergs Arch Pharmacol ， 2024 ， 397 （ 5 ）： 3351 - 3362 .
SPEED V ， GREEN B ， ROBERTS L N ， et al . Fixed dose rivaroxaban can be used in extremes of bodyweight：a population pharmacokinetic analysis [J ] . J Thromb Haemost ， 2020 ， 18 （ 9 ）： 2296 - 2307 .
GUIMARÃES H P ， LOPES R D ， DE BARROS E SILVA P G M ， et al . Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve [J ] . N Engl J Med ， 2020 ， 383 （ 22 ）： 2117 - 2126 .
ALFIREVIC A ， DOWNING J ， DARAS K ， et al . Has the introduction of direct oral anticoagulants（DOACs）in England increased emergency admissions for bleeding conditions? A longitudinal ecological study [J ] . BMJ Open ， 2020 ， 10 （ 5 ）： e033357 .
杨晨 ， 袁恒杰 ， 李正翔 . 1例误服大剂量利伐沙班患者的血药浓度监测及临床处置 [J ] . 中国医院药学杂志 ， 2022 ， 42 （ 11 ）： 1175 - 1177 .
YANG C ， YUAN H J ， LI Z X . Plasma concentration monitoring and clinical procedures for a patient with accidental high-dose administration of rivaroxaban [J ] . Chin J Hosp Pharm ， 2022 ， 42 （ 11 ）： 1175 - 1177 .
KUBITZA D ， BECKA M ， ROTH A ， et al . The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban：an oral，direct factor Ⅹa inhibitor [J ] . J Clin Pharmacol ， 2013 ， 53 （ 3 ）： 249 - 255 .
KRAUSS E S ， CRONIN M ， DENGLER N ， et al . The effect of BMI and gender on bleeding events when rivaroxaban is administered for thromboprophylaxis following total hip and total knee arthroplasty [J ] . Semin Thromb Hemost ， 2019 ， 45 （ 2 ）： 180 - 186 .
ANDREOTTI F ， GEISLER T ， COLLET J P ， et al . Acute，periprocedural and long-term antithrombotic therapy in older adults：2022 update by the ESC Working Group on thrombosis [J ] . Eur Heart J ， 2023 ， 44 （ 4 ）： 262 - 279 .
KAMPOURAKI E ， AVERY P ， BISS T ， et al . Assessment of exposure to direct oral anticoagulants in elderly hospitalised patients [J ] . Br J Haematol ， 2021 ， 195 （ 5 ）： 790 - 801 .
丁征 . 直接口服抗凝药合理用药和处方质量评价药学建议 [J ] . 中国循环杂志 ， 2024 ， 39 （ 3 ）： 217 - 227 .
DING Z . Pharmaceutical recommendation on rational use and the prescription quality evaluation of direct oral anticoagulants [J ] . Chin Circ J ， 2024 ， 39 （ 3 ）： 217 - 227 .
0
Views
171
下载量
0
CSCD
- L-PDFDownload
- WORDDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
- Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号
公网安备50010302001817 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.